These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16965873)

  • 1. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
    Lehmann J; DeNardo GL; Yuan A; Shen S; O'Donnell RT; Richman CM; DeNardo SJ
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1192-8. PubMed ID: 16965873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
    J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ; DeNardo GL; Yuan A; Richman CM; O'Donnell RT; Lara PN; Kukis DL; Natarajan A; Lamborn KR; Jacobs F; Siantar CL
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
    DeNardo GL; DeNardo SJ
    Cancer Biother Radiopharm; 2004 Feb; 19(1):85-92. PubMed ID: 15068616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM; DeNardo SJ; O'Donnell RT; Goldstein DS; Shen S; Kukis DL; Kroger LA; Yuan A; Boniface GR; Griffith IJ; DeNardo GL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL; Kroger LA; Meares CF; Richman CM; Salako Q; Shen S; Lamborn KR; Peterson JJ; Miers LA; Zhong GR; DeNardo SJ
    Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
    Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
    Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.
    O'Donnell RT; DeNardo SJ; Yuan A; Shen S; Richman CM; Lara PN; Griffith IJ; Goldstein DS; Kukis DL; Martinez GS; Mirick GR; DeNardo GL; Meyers FJ
    Clin Cancer Res; 2001 Jun; 7(6):1561-8. PubMed ID: 11410491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
    Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
    J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
    Odom-Maryon TL; Williams LE; Chai A; Lopatin G; Liu A; Wong YC; Chou J; Clarke KG; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1959-66. PubMed ID: 9430477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
    Foss FM; Raubitscheck A; Mulshine JL; Fleisher TA; Reynolds JC; Paik CH; Neumann RD; Boland C; Perentesis P; Brown MR; Frincke JM; Lollo CP; Larson SM; Carrasquillo JA
    Clin Cancer Res; 1998 Nov; 4(11):2691-700. PubMed ID: 9829731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ; Kramer EL; O'Donnell RT; Richman CM; Salako QA; Shen S; Noz M; Glenn SD; Ceriani RL; DeNardo GL
    J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
    J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
    Deb N; Goris M; Trisler K; Fowler S; Saal J; Ning S; Becker M; Marquez C; Knox S
    Clin Cancer Res; 1996 Aug; 2(8):1289-97. PubMed ID: 9816299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.